159 related articles for article (PubMed ID: 30801544)
1. Renal Safety of Intravenous Gadolinium-enhanced MRI in Patients Following Liver Transplantation.
Flynn MM; Parekh AN; Parikh MR; Sood A; Shaffer KM; Runge TM; Lipowska AM; Perez SD; Sakaria SS; Subramanian RM
Transplantation; 2019 Jun; 103(6):e159-e163. PubMed ID: 30801544
[TBL] [Abstract][Full Text] [Related]
2. Renal safety of intravenous gadolinium-enhanced magnetic resonance imaging in patients awaiting liver transplantation.
Shaffer KM; Parikh MR; Runge TM; Perez SD; Sakaria SS; Subramanian RM
Liver Transpl; 2015 Nov; 21(11):1340-6. PubMed ID: 25786913
[TBL] [Abstract][Full Text] [Related]
3. Evaluation of the incidence of nephrogenic systemic fibrosis in patients with moderate renal insufficiency administered gadobenate dimeglumine for MRI.
Bryant BJ; Im K; Broome DR
Clin Radiol; 2009 Jul; 64(7):706-13. PubMed ID: 19520215
[TBL] [Abstract][Full Text] [Related]
4. Nephrogenic systemic fibrosis: change in incidence following a switch in gadolinium agents and adoption of a gadolinium policy--report from two U.S. universities.
Altun E; Martin DR; Wertman R; Lugo-Somolinos A; Fuller ER; Semelka RC
Radiology; 2009 Dec; 253(3):689-96. PubMed ID: 19789233
[TBL] [Abstract][Full Text] [Related]
5. Gadobenate Dimeglumine Administration and Nephrogenic Systemic Fibrosis: Is There a Real Risk in Patients with Impaired Renal Function?
Nandwana SB; Moreno CC; Osipow MT; Sekhar A; Cox KL
Radiology; 2015 Sep; 276(3):741-7. PubMed ID: 25875973
[TBL] [Abstract][Full Text] [Related]
6. Incidence of Nephrogenic Systemic Fibrosis Using Gadobenate Dimeglumine in 1423 Patients With Renal Insufficiency Compared With Gadodiamide.
Bruce R; Wentland AL; Haemel AK; Garrett RW; Sadowski DR; Djamali A; Sadowski EA
Invest Radiol; 2016 Nov; 51(11):701-705. PubMed ID: 26885631
[TBL] [Abstract][Full Text] [Related]
7. Quarter-dose (0.025 mmol/kg) gadobenate dimeglumine for abdominal MRI in patients at risk for nephrogenic systemic fibrosis: preliminary observations.
de Campos RO; Heredia V; Ramalho M; De Toni MS; Lugo-Somolinos A; Fuller ER; Semelka RC
AJR Am J Roentgenol; 2011 Mar; 196(3):545-52. PubMed ID: 21343495
[TBL] [Abstract][Full Text] [Related]
8. Prospective Cohort Study of Nephrogenic Systemic Fibrosis in Patients With Stage 3-5 Chronic Kidney Disease Undergoing MRI With Injected Gadobenate Dimeglumine or Gadoteridol.
Soulez G; Bloomgarden DC; Rofsky NM; Smith MP; Abujudeh HH; Morgan DE; Lichtenstein RJ; Schiebler ML; Wippold FJ; Russo C; Kuhn MJ; Mennitt KW; Maki JH; Stolpen A; Liou J; Semelka RC; Kirchin MA; Shen N; Pirovano G; Spinazzi A
AJR Am J Roentgenol; 2015 Sep; 205(3):469-78. PubMed ID: 26295633
[TBL] [Abstract][Full Text] [Related]
9. Notice of Withdrawal: No Incidence of Nephrogenic Systemic Fibrosis after Gadobenate Dimeglumine Administration in Patients Undergoing Dialysis or Those with Severe Chronic Kidney Disease.
Martin DR; Kalb B; Mittal A; Salman K; Vedantham S; Mittal PK
Radiology; 2018 Jan; 286(1):113-119. PubMed ID: 28731375
[TBL] [Abstract][Full Text] [Related]
10. Incidence of immediate gadolinium contrast media reactions.
Prince MR; Zhang H; Zou Z; Staron RB; Brill PW
AJR Am J Roentgenol; 2011 Feb; 196(2):W138-43. PubMed ID: 21257854
[TBL] [Abstract][Full Text] [Related]
11. The use of gadolinium for arterial interventions.
Sambol EB; Van der Meer JG; Graham A; Goldstein LJ; Karwowski JK; Dayal R; Derubertis B; Kent KC
Ann Vasc Surg; 2011 Apr; 25(3):366-76. PubMed ID: 21288688
[TBL] [Abstract][Full Text] [Related]
12. Observational study on the safety profile of gadoterate meglumine in 35,499 patients: The SECURE study.
Soyer P; Dohan A; Patkar D; Gottschalk A
J Magn Reson Imaging; 2017 Apr; 45(4):988-997. PubMed ID: 27726239
[TBL] [Abstract][Full Text] [Related]
13. Imaging patients with kidney disease: how do we approach contrast-related toxicity?
Perazella MA; Reilly RF
Am J Med Sci; 2011 Mar; 341(3):215-21. PubMed ID: 21139495
[TBL] [Abstract][Full Text] [Related]
14. Low risk for nephrogenic systemic fibrosis in nondialysis patients who have chronic kidney disease and are investigated with gadolinium-enhanced magnetic resonance imaging.
Chrysochou C; Power A; Shurrab AE; Husain S; Moser S; Lay J; Salama AD; Kalra PA
Clin J Am Soc Nephrol; 2010 Mar; 5(3):484-9. PubMed ID: 20093350
[TBL] [Abstract][Full Text] [Related]
15. Observational study on the incidence of nephrogenic systemic fibrosis in patients with renal impairment following gadoterate meglumine administration: the NSsaFe study.
McWilliams RG; Frabizzio JV; De Backer AI; Grinberg A; Maes BD; Zobel BB; Gottschalk A
J Magn Reson Imaging; 2020 Feb; 51(2):607-614. PubMed ID: 31287213
[TBL] [Abstract][Full Text] [Related]
16. Absence of potential gadolinium toxicity symptoms following 22,897 gadoteric acid (Dotarem®) examinations, including 3,209 performed on renally insufficient individuals.
Young LK; Matthew SZ; Houston JG
Eur Radiol; 2019 Apr; 29(4):1922-1930. PubMed ID: 30276674
[TBL] [Abstract][Full Text] [Related]
17. Comparison between gadolinium and iodine contrast for percutaneous intervention in atherosclerotic renal artery stenosis: clinical outcomes.
Kane GC; Stanson AW; Kalnicka D; Rosenthal DW; Lee CU; Textor SC; Garovic VD
Nephrol Dial Transplant; 2008 Apr; 23(4):1233-40. PubMed ID: 18256017
[TBL] [Abstract][Full Text] [Related]
18. Safety of meglumine gadoterate (Gd-DOTA)-enhanced MRI compared to unenhanced MRI in patients with chronic kidney disease (RESCUE study).
Deray G; Rouviere O; Bacigalupo L; Maes B; Hannedouche T; Vrtovsnik F; Rigothier C; Billiouw JM; Campioni P; Ferreiros J; Devos D; Alison D; Glowacki F; Boffa JJ; Marti-Bonmati L
Eur Radiol; 2013 May; 23(5):1250-9. PubMed ID: 23212275
[TBL] [Abstract][Full Text] [Related]
19. Acute Adverse Events Following Gadolinium-based Contrast Agent Administration: A Single-Center Retrospective Study of 281 945 Injections.
McDonald JS; Hunt CH; Kolbe AB; Schmitz JJ; Hartman RP; Maddox DE; Kallmes DF; McDonald RJ
Radiology; 2019 Sep; 292(3):620-627. PubMed ID: 31264948
[TBL] [Abstract][Full Text] [Related]
20. Contrast-induced acute kidney injury in cirrhotic patients. A retrospective analysis.
Safi W; Rauscher I; Umgelter A
Ann Hepatol; 2015; 14(6):895-901. PubMed ID: 26436362
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
